ReviewCurrent pharmaceutical design2025
The Progress of Immune Cells-induced Inflammatory Response in Gout.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatiotemporal immune gradients in gout: immune response-driven activation of the NLRP3-IL-1β axis and its transition to trained immunity.Frontiers in immunology · 2026Review
- Total Glucosides of Paeony (TGP) Inhibits Macrophages Infiltration and NLRP3-Mediated Inflammatory Response in Acute Gouty Arthritis Mice.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gout, based on hyperuricemia, is an immune disease characterized by redness and pain caused by monosodium urate (MSU) deposition in the joints. Inflammation is the fundamental cause of gout symptoms, and many immune cells, such as monocytes/macrophages, neutrophils, and T lymphocytes, have been shown to be involved in various processes of pathological progress. This study reviews the changes and functions of different immune cells during the occurrence and development of gout, focusing on the mechanisms and signaling pathways by which macrophages activate nod-like receptor pyrin-containing 3 (NLRP3) inflammasome to initiate gout inflammation in order to further elucidate the pathogenesis of gout and provide new targets for the research of anti-gout drugs.
Indexed as
Identifiers
40148294What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.